In vivo measurement of lymphocyte kinetics during immune reconstitution after hematopoietic stem cell transplantation using [6,6-2H2]-glucose labeling

In vivo measurement of lymphocyte kinetics during immune reconstitution after hematopoietic stem cell transplantation using [6,6-2H2]-glucose labeling - SILAS: Stable Isotope Labeling After Stemcelltransplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39524

Enrollment

Registered

2012-01-03

Start date

2012-08-27

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stemcell transplatation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Patients who underwent autologous or allogeneic stem cell transplantation because of a hematological malignancy • Complete remission before HSCT • Age 18-65 years • WHO performance score 0-2 • Outpatient clinic patients Inclusion criteria - specific for autologous HSCT • Indication for HSCT: relapsed non-Hodgkin*s lymphoma • Remission-induction chemotherapy schedule including Rituximab • Conditioning regimen: BEAM chemotherapy (BCNU (Carmustine), Ara-C (cytarabine), etoposide (VP16), Melphalan) Inclusion criteria - specific for allogeneic HSCT • Indication for HSCT: acute myeloid leukemia (AML) • Type of transplant: non-mismatched sibling donor (n=5) and matched unrelated donor (MUD; n=5), non-T cell depleted peripheral blood derived stem cell transplant • Conditioning regimen (myeloablative): cyclophosphamide and total body irradiation for sibling donors; cyclophosphamide, total body irradiation and anti-thymocyte globulin for unrelated donors • No or minimal immune suppression (prednisone

Exclusion criteria

Exclusion criteria: • Acute graft-versus-host disease or infectious complications necessitating hospital admission; • Active hematological malignancy; • HIV, hepatitis B, hepatitis C infection • Pre-treatment with immunomodulatory or lymphocyte depleting drugs such as lenalidomide, fludarabine or alemtuzumab • AML relapse and/or previous autologous or allogeneic HSCT • Significant renal, hepatic or cardiac dysfunction • Diabetes mellitus type 1, DM type 2 • Alcohol and/or drug abuse • Unwilling or not capable to use effective means of birthcontrol

Design outcomes

Primary

Measure	Time frame
Lymphocyte subset production rates and life spans during immune recovery following HSCT	—

Countries

Netherlands

Outcome results